Main Article Content
Triple negative breast neoplasms, Prognosis, Neoadjuvant therapy, Survival rate
Background: Triple-negative breast cancer (TNBC) is defined as tumors without estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This cancer is associated with higher rates of recurrence risk when compared to other subtypes of breast cancers. In this study, we aimed to explore the basic clinicopathological characteristics, prognosis, and recurrence patterns of TNBC patients.
Methods: In the current study, forty-five TNBC female patients operated on for breast cancer in the General Surgery Clinic of Kayseri City Training and Research Hospital between 2016 and 2021 were included and retrospectively evaluated.
Results: The percentage of TNBC was 12% of the 502 breast cancer patients who could access all three pieces of receptor information. The mean age of the patients was 58.9±15.2 years (27-90), and the mean BMI was 30.4±5.17 (21.5-40.6). It was observed that the most common histological subtype was invasive ductal carcinoma, and at the time of diagnosis, 11 patients were stage 1 (24.4%), 31 patients were stage 2 (68.8%), 2 patients were stage 3 (4.4%), and 1 patient was stage 4 (2.2%). During the follow-up period, 11 patients (24,4%) developed metastasis and the most common sites were the brain and bones. The mean time from diagnosis to metastasis was 20.7±5.75 (12-29) months. The 3-year disease-free survival was 62%, and the 3-year overall survival (OS) was 70%.
Conclusion: TNBCs are cancers with varying prevalence, poor prognosis, and limited treatment alternatives. The prevalence of TNBC in our center was found to be lower than the literature rates and consistent with the literature, the lymph node stage was related to poor OS and disease free survival (DFS).
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48.
3. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430-42.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34.
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-502.
6. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(1):307-14.
7. Budakoglu B, Altundag K, Aksoy S, Kaplan MA, Ozdemir NY, et al. Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey. J BUON. 2014;19(4):872-8.
8. Ozmen V, Ozmen T, Dogru V. Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. Eur J Breast Health. 2019;15(3):141-6.
9. Yildiz B, Fidan E, Ozdemir F, Sezen O, Kavgaci H, et al. Clinicopathological Characteristics of Triple-negative Breast Cancers in the Northeast Region of Turkey. Balkan Med J. 2014;31(2):126-31.
10. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247-69.
11. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):876-84.
12. Chen L, Cook LS, Tang MT, Porter PL, Hill DA, et al. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Res Treat. 2016;157(3):545-54.
13. Al Jarroudi O, Abda N, Seddik Y, Brahmi SA, Afqir S. Overweight: is it a prognostic factor in women with triple-negative breast cancer? Asian Pacific J Cancer Prev. 2017;18(6):1519.
14. Nazari SS, Mukherjee P. An overview of mammographic density and its association with breast cancer. Breast Cancer. 2018;25(3):259-67.
15. Mema E, Schnabel F, Chun J, Kaplowitz E, Price A, et al. The relationship of breast density in mammography and magnetic resonance imaging in women with triple negative breast cancer. Eur J Radiol. 2020;124:108813.
16. Bae MS, Moon HG, Han W, Noh DY, Ryu HS, et al. Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence. Radiology. 2016;278(2):356-64.
17. Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz V, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013;15(6):R104.
18. Shieh Y, Scott CG, Jensen MR, Norman AD, Bertrand KA, et al. Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. Breast Cancer Res. 2019;21(1):48.
19. Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543-61.
20. Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018;18(1):265.
21. Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169-80.
22. Chen H, Wu J, Zhang Z, Tang Y, Li X, et al. Association between BRCA status and triple-negative breast cancer: a meta-analysis. Front Pharmacol. 2018;9:909.
23. Daly MB, Pal T, Berry MP, Buys SS, Dickson P, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(1):77-102.
24. Zhu X, Chen L, Huang B, Wang Y, Ji L, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10(1):225.
25. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-81.
26. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638-45.
27. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72.
28. Bagegni NA, Tao Y, Ademuyiwa FO. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. PLoS One. 2019;14(9):e0222358.
29. Xia LY, Hu QL, Zhang J, Xu WY, Li XS. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases. World J Surg Oncol. 2020;18(1):129.
30. Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017;376(22):2147-59.
31. Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021;39(13):1485-505.
Article Statistics :Views : 91 | Downloads : 8 : 1